Earnings ·
Reports Q3 revenue of $411.2M and completes $2.1B debt refinancing
IARTIntegra Lifesciences Holdings Corp
Integra LifeSciences reported third-quarter revenues of $411.2 million, a 2.5% organic increase, with adjusted earnings per diluted share of $0.59 compared to $0.54 in the prior year period. The company also announced it completed a $2.1 billion debt refinancing on October 19, consisting of a new senior secured credit facility and $450 million in 9.5% senior secured notes due 2033, which extended maturities and enhanced financial flexibility. Full-year revenue guidance remains at $1.634 billion to $1.654 billion with adjusted EPS expected between $2.30 and $2.40. Integra LifeSciences is a global medical technology company focused on neurosurgery and tissue reconstruction products.